Stuart A. Aaronson
0000-0002-4643-0474
Publication & Citation Trends
Publications
0 total
Abstract 2940: Tumor-selective dimeric and monomeric RAF targeting with a next-generation Type 1 RAF inhibitor.
Cited by 0
Semantic Scholar
Abstract 3898: Profiling tumor selectivity of state- and paralog-selective RAS inhibitors through a signaling inhibition index (SII).
Cited by 0
Semantic Scholar
Abstract 2948: A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition.
Cited by 0
Semantic Scholar
RAS mutation-specific responses to paralog- and state-selective RAS inhibitors.
Cited by 0
Semantic Scholar
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Cited by 1
Semantic Scholar
Wnk kinases are positive regulators of canonical Wnt/β‐catenin signalling OA
Cited by 26
Semantic Scholar
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes OA
Cited by 707
Semantic Scholar
Growth Factor and Receptor Tyrosine Kinases
Cited by 7
Semantic Scholar
Research Topics
Virus-based gene therapy research
(157)
Animal Virus Infections Studies
(77)
Cancer-related Molecular Pathways
(76)
Viral Infectious Diseases and Gene Expression in Insects
(51)
RNA Interference and Gene Delivery
(43)
Affiliations
Oregon National Primate Research Center
Broad Institute
Northwestern University
Oak Ridge National Laboratory
Texas Biomedical Research Institute